A high rate of serious infections in a phase III trial of the anti-CD20 monoclonal antibody ocrelizumab for class III/IV lupus nephritis led to early termination of the study. Thus, despite the partial results (n = 223) suggesting that this drug might have some efficacy—overall renal response rate was improved, although not statistically significantly, in the ocrelizumab group compared with the placebo group (66.9% versus 54.7%)—the risks associated with ocrelizumab use seem to outweigh the benefits for patients with this disease.